Irritable Bowel Syndrome Treatment for Patients With Diarrhea and Abdominal Pain Offers New Opportunity for Relief

IBS Treatment

Patients with Diarrhea Predominant Irritable Bowel Syndrome (IBS-d) often suffer from abdominal pain associated with urgent and frequent or loose bowel movements. These people frequently have significant reduction in Quality of Life, due to difficulty in social settings, restaurants, travel, commuting, work and school, with disruptions due to abdominal pain and bowel urgency and frequency. Lotrenex (alosetron) is the only FDA approved agent for this condition. Imodium relieves diarrhea, but has not been demonstrated to consistently reduce abdominal pain. Constipation is a frequent side effect. Many sufferers use habit forming medications such as Librax (clinidium), Lomotil (atropine), and narcotic pain relievers. Antispasmodics as dicyclomine and hyoscyamine are frequently prescribed but have never been demonstrated to be effective. Patients are looking for new choices to improve Quality of Life and relieve global symptoms. New Irritable Bowel Syndrome Treatment available at Progressive Gastroenterology may be the answer you need. 

Clinical studies have shown a new agent may be effective in providing relief and symptom control for diarrhea predominant Irritable Bowel Syndrome. Dr. David Gutman and the research team of New York Heart Research Foundation are studying this new treatment as part of a large multicenter trial that will involve 1125 patients. The study will take 58 weeks to perform, and includes one to four weeks of screening, 52 weeks of treatment, and two weeks of followup. There will be three groups of patients. These people will randomly either take the study drug in one of two doses twice a day, or a look alike but inactive pill called placebo twice a day. Neither Dr Gutman, nor the patient will know which of the three doses the patient has been randomly assigned to .

Patients who participate will get for their participation:

  • Free treatment.
  • Free medication.
  • Free office visits without copay.
  • Insurance is not required nor asked for once you consent to the study, for study related visits.
  • Free diagnostic laboratories.
  • Free EKG of the heart.
  • Compensation for time and travel is $50 per visit.
  • There are 12 to 14 visits and the compensation is paid at the end of the participation in the study.
  • Opportunity to have relief from IBS-d symptoms.
  • Opportunity to be a part of a major medical development that is greatly in need by millions of people.
  • You may discontinue treatment at anytime for any reason.
  • You will receive clear explanations of Irritable Bowel Syndrome and treatment options by Dr. David Gutman, a leading expert on Irritable Bowel Syndrome and a Principal Investigator of multiple clinical studies for the treatment of IBS.
  • Your questions will be answered by the leader in the field of IBS in the Long Island and New York Metro area.

For more information, call Patricia Hodnett, R.N., M.S.N., C.C.R.C. at (516) 739-4982

Photo By: Mike Baird CC BY 2.0

0
Shares
Dr. David Gutman
 

Long Island's Premier Center for evaluation and treatment of Reflux, GERD, IBS, Eosinophilic Esophagitis, and Laryngopharyngeal Reflux. Dr. Gutman is the Director of Reflux Care of New York. He is a leading authority in the fields of Gastroesophageal Reflux Disorder (GERD), Laryngopharyngeal Reflux (LPR), Irritable Bowel Syndrome (IBS), Eosinophilic Esophagitis, and Non Cardiac Chest Pain. Dr. Gutman's approach to complicated digestive problems, utilizing a breadth of clinical experience with state of the art technologies has allowed him to benefit many patients who have struggled with GERD, LPR, IBS, Barrett's esophagus, Inflammatory Bowel Disease, and World Trade Center Syndrome. He is the only Long Island Gastroenterologist expert in Endoscopic Fundoplication (Esophyx), Transnasal Endoscopy, and the first to use Wireless esophageal acid testing without any nasal tubes. Demand the very best at Reflux Care.

Click Here to Leave a Comment Below 2 comments